Funding for this research was provided by:
Prostate Cancer Foundation
Text and Data Mining valid from 2019-10-25
Received: 28 February 2019
Accepted: 26 September 2019
First Online: 25 October 2019
Ethics approval and consent to participate
: All animal experiments were performed in specific pathogen-free facilities accredited by the American Association for the Accreditation of Laboratory Animal Care (AAALAC) with protocols approved by the Animal Care and Use Committee of the Columbia University School of Medicine (New York, NY).
: Not applicable.
: The authors declare competing financial interests. CGD has consulted for Amplimmune, Bristol Myers Squibb (BMS), Merck, and Roche-Genentech, all of whom have either anti-PD-1 or anti-PD-L1 reagents in various stages of clinical development. In addition, CGD has previously received sponsored research funding from BMS. WM has no conflicts of interest to declare.